Combination therapy for treatment of refractory depression

• US 6,960,577 B2
• Filed: 05/10/2002
• Issued: 11/01/2005
• Est. Priority Date: 05/22/1998
• Status: Expired due to Term

• Current Assignee: Eli Lilly and Company
• Original Assignee: Eli Lilly and Company
• Inventors: Tollefson, Gary Dennis
• Primary Examiner(s): Spivack, Phyllis G.
• Application Number:
  US10/144,159
• Publication Number:
  US 20030212060A1
• Time in Patent Office: 1,271 Days
• Field of Search: 514/215, 514/649
• US Class Current: 514/215
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/137 Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
• CPC Class Codes: A61K 31/445 Non condensed piperidines, e.g. piperocaine
• CPC Class Codes: A61K 31/519 ortho- or peri-condensed with heterocyclic rings
• CPC Class Codes: A61K 31/551 having two nitrogen atoms, e.g. dilazep
• CPC Class Codes: A61K 31/5513 1,4-Benzodiazepines, e.g. diazepam or clozapine

Abstract

Methods for treating a patient suffering from or susceptible to treatment resistant major depression comprising administering olanzapine and fluoxetine are disclosed.

Claims

1. A method for treating a patient suffering from or susceptible to treatment resistant major depression, comprising administering to said patient an effective amount of a first component which is olanzapine or a pharmaceutically acceptable salt thereof, in combination with an effective amount of a second component which is fluoxetine, or a phannaceutically acceptable salt thereof.

2. A method according to claim 1 where the administration of the compounds is oral.

3. A method for treating a patient suffering from or susceptible to treatment resistant major depression, comprising administering to said patient an effective amount of a first component which is olanzapine, in combination with an effective amount of a second component which is fluoxetine.

4. A method for treating a patient suffering from or susceptible to treatment resistant major depression, comprising administering to said patient an effective amount of a first component which is olanzapine in combination with an effective amount of a second component which is fluoxetine hydrochloride.